Manufacturing, Cell-Line Selection

Cytiva Acquires CEVEC, Boosts Cell Line Development Capabilities

October 10, 2022

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.

Plant-based Expression Systems are Gaining Mainstream Advantage

July 02, 2022

Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure.

Outlining Cell Lines’ Future with Engineering Approaches

March 02, 2022

The use of bioengineering offers practical tools for the evolution of host cells.

Catalent Biologics Launches New Cell Line Expression Technology

July 22, 2021

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

Berkeley Lights Launches Assay Series for Early Cell-Line Development Yield and Product Quality

April 06, 2021

The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.

Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture

January 02, 2021

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center

October 29, 2020

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.

New EpiMOGRIFY Technology Platform Offers Development Support for Allogeneic Cell Therapies

October 29, 2020

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

October 02, 2020

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines

September 03, 2020

This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.